These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A; Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794 [TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333 [TBL] [Abstract][Full Text] [Related]
4. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685 [TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children. Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752 [TBL] [Abstract][Full Text] [Related]
6. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164 [No Abstract] [Full Text] [Related]
7. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience. Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796 [TBL] [Abstract][Full Text] [Related]
8. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag. Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100 [TBL] [Abstract][Full Text] [Related]
9. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia? Huan Ng C; Jang-Milligan F; Schultz KR Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932 [No Abstract] [Full Text] [Related]
10. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Yaman Y; Elli M; Şahin Ş; Özdilli K; Bilgen H; Bayram N; Nepesov S; Anak S Pediatr Transplant; 2021 Aug; 25(5):e13962. PubMed ID: 33452850 [TBL] [Abstract][Full Text] [Related]
11. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation. Karataş A; Göker H; Demiroğlu H; Malkan ÜY; Velet M; Çınar OE; Erdoğdu B; Karadeniz M; Sayınalp N; Aksu S; Haznedaroğlu İC; Özcebe Oİ; Büyükaşık Y Turk J Med Sci; 2022 Apr; 52(2):413-419. PubMed ID: 36161632 [TBL] [Abstract][Full Text] [Related]
15. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience. Yan F; Lu N; Gu Z; Huang W; Wang S; Gao X; Dou L; Li F; Wang L; Li M; Liu D; Gao C Ann Hematol; 2022 Feb; 101(2):397-408. PubMed ID: 34735613 [TBL] [Abstract][Full Text] [Related]
16. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children. Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480 [TBL] [Abstract][Full Text] [Related]
17. [Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation]. Ma YR; Huang XJ; Mo XD; Han W; Yan CH; Chen Y; Ji Y; Chen YY; Wang Y; Zhang XH; Liu KY; Xu LP Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1065-1069. PubMed ID: 28088971 [TBL] [Abstract][Full Text] [Related]
18. Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation. Zhou M; Li T; Zhang P; Lai Y; Sheng L; Ouyang G Ann Hematol; 2024 May; 103(5):1697-1704. PubMed ID: 38536476 [TBL] [Abstract][Full Text] [Related]
19. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Fu H; Zhang X; Han T; Mo X; Wang Y; Chen H; Han W; Wang J; Wang F; Yan C; Zhang Y; Sun Y; Liu K; Huang X; Xu L Bone Marrow Transplant; 2019 Aug; 54(8):1310-1318. PubMed ID: 30664724 [TBL] [Abstract][Full Text] [Related]
20. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Katsutani S; Tomiyama Y; Kimura A; Miyakawa Y; Okamoto S; Okoshi Y; Ninomiya H; Kosugi H; Ishii K; Ikeda Y; Hattori T; Katsura K; Kanakura Y Int J Hematol; 2013 Sep; 98(3):323-30. PubMed ID: 23896965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]